-
公开(公告)号：US20230355609A1
公开(公告)日：2023-11-09
申请号：US18092723
申请日：2023-01-03
申请人： Quixgen, Inc.
发明人： Yusheng Xiong , Hong-Ping Guan , Wenjun Huang
IPC分类号： A61P17/10 , A61K31/145 , A61K31/18 , A61K31/192 , A61K31/444 , A61K31/65 , A61K47/32 , C07D491/107 , A61P3/04 , A61K9/00 , A61K31/575 , A61K31/616 , A61K31/7056 , A61K38/26 , A61K31/4709 , A61K31/197 , A61K31/203 , A61K31/401 , A61K31/438 , A61K47/10 , A61P1/16 , A61K31/40 , A61K31/4164 , A61K31/7048 , A61K48/00 , C07D519/00
CPC分类号： A61K31/4709 , A61K9/0014 , A61K31/145 , A61K31/18 , A61K31/192 , A61K31/197 , A61K31/203 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/438 , A61K31/444 , A61K31/575 , A61K31/616 , A61K31/65 , A61K31/7048 , A61K31/7056 , A61K38/26 , A61K47/10 , A61K47/32 , A61K48/005 , A61P1/16 , A61P3/04 , A61P17/10 , C07D491/107 , C07D519/00
摘要： Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11541046B2
公开(公告)日：2023-01-03
申请号：US16627627
申请日：2018-06-29
申请人： Yusheng Xiong , Hong-Ping Guan , Wenjun Huang , Quixgen, Inc.
发明人： Yusheng Xiong , Hong-Ping Guan , Wenjun Huang
IPC分类号： A61K31/4709 , A61P17/10 , A61P1/16 , A61P3/04 , A61K9/00 , A61K31/145 , A61K31/18 , A61K31/192 , A61K31/197 , A61K31/203 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/438 , A61K31/444 , A61K31/575 , A61K31/616 , A61K31/65 , A61K31/7048 , A61K31/7056 , A61K38/26 , A61K47/10 , A61K47/32 , A61K48/00 , C07D491/107 , C07D519/00
摘要： Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20210145822A1
公开(公告)日：2021-05-20
申请号：US16627627
申请日：2018-06-29
申请人： Quixgen, Inc.
发明人： Yusheng Xiong , Hong-Ping Guan , Wenjun Huang
IPC分类号： A61K31/4709 , A61K9/00 , A61P1/16 , A61P17/10 , A61P3/04 , C07D491/107 , C07D519/00 , A61K31/438 , A61K31/444 , A61K47/10 , A61K47/32 , A61K31/7056 , A61K31/7048 , A61K31/4164 , A61K31/18 , A61K31/65 , A61K31/192 , A61K31/203 , A61K31/616 , A61K31/575 , A61K48/00 , A61K31/40 , A61K38/26 , A61K31/197 , A61K31/401 , A61K31/145
摘要： Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
-
公开(公告)号：US12102633B2
公开(公告)日：2024-10-01
申请号：US18092723
申请日：2023-01-03
申请人： Quixgen, Inc.
发明人： Yusheng Xiong , Hong-Ping Guan , Wenjun Huang
IPC分类号： A61K31/4709 , A61K9/00 , A61K31/145 , A61K31/18 , A61K31/192 , A61K31/197 , A61K31/203 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/438 , A61K31/444 , A61K31/575 , A61K31/616 , A61K31/65 , A61K31/7048 , A61K31/7056 , A61K38/26 , A61K47/10 , A61K47/32 , A61K48/00 , A61P1/16 , A61P3/04 , A61P17/10 , C07D491/107 , C07D519/00
CPC分类号： A61K31/4709 , A61K9/0014 , A61K31/145 , A61K31/18 , A61K31/192 , A61K31/197 , A61K31/203 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/438 , A61K31/444 , A61K31/575 , A61K31/616 , A61K31/65 , A61K31/7048 , A61K31/7056 , A61K38/26 , A61K47/10 , A61K47/32 , A61K48/005 , A61P1/16 , A61P3/04 , A61P17/10 , C07D491/107 , C07D519/00
摘要： Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
